Wakunaga Pharmaceutical Of Japan To Enter Indian Market
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Wakunaga Pharmaceutical announced plans to enter the Indian market within the year. The company plans to market over-the-counter drug Kyoleopin and supplements through local Indian wholesalers. Wakunaga's move is to seize upon India's economic development and demand for health products; the company expects to reach ¥100 million in sales during the first year. Wakunaga also plans to enter the Brazilian market, and over the long term, Wakunaga hopes to expand shares in the European market. (Click here for more - Japanese language
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.